Yu Xia1, Stephen Forest2, Patricia Friedmann2, Lin-Chiang Chou2, Snehal Patel3, Ulrich Jorde3, Daniel Goldstein2. 1. Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, New York. Electronic address: yxia@montefiore.org. 2. Department of Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, New York. 3. Department of Medicine, Montefiore Medical Center, Bronx, New York.
Abstract
BACKGROUND: Limited data exist on factors predicting prolonged survival in left ventricular assist device (LVAD) recipients. We sought to identify patient characteristics and complications associated with prolonged survival. METHODS: We conducted retrospective review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database, including primary continuous-flow LVAD recipients, between May 2012 and March 2013. Patients were identified as having survived with a device in place after 3 years or not, conditional on having initially survived 6 months. Patients who received a transplant, underwent explant due to recovery, or were lost to follow-up before 3 years were excluded. Multivariate logistic regression evaluated perioperative factors and adverse events within 6 months associated with long survival. RESULTS: Of 1,116 patients who survived past the initial 6 months, 725 (65%) survived beyond 3 years. On univariate analysis, long-term survivors were significantly younger, were less likely to be white, supported for destination therapy, have diabetes, solid-organ cancer, or take amiodarone. On multivariate analysis, factors associated with increased odds of death at 3 years included diabetes, amiodarone use, and developing stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis within 6 months of implantation. CONCLUSIONS: Preoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients.
BACKGROUND: Limited data exist on factors predicting prolonged survival in left ventricular assist device (LVAD) recipients. We sought to identify patient characteristics and complications associated with prolonged survival. METHODS: We conducted retrospective review of the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) database, including primary continuous-flow LVAD recipients, between May 2012 and March 2013. Patients were identified as having survived with a device in place after 3 years or not, conditional on having initially survived 6 months. Patients who received a transplant, underwent explant due to recovery, or were lost to follow-up before 3 years were excluded. Multivariate logistic regression evaluated perioperative factors and adverse events within 6 months associated with long survival. RESULTS: Of 1,116 patients who survived past the initial 6 months, 725 (65%) survived beyond 3 years. On univariate analysis, long-term survivors were significantly younger, were less likely to be white, supported for destination therapy, have diabetes, solid-organ cancer, or take amiodarone. On multivariate analysis, factors associated with increased odds of death at 3 years included diabetes, amiodarone use, and developing stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis within 6 months of implantation. CONCLUSIONS: Preoperative diabetes and amiodarone use were associated with poor long-term survival in LVAD recipients. Development of early complications of stroke, gastrointestinal bleeding, hemolysis, or pump thrombosis was also associated with poor long-term survival. Early diagnosis and treatment of these complications may improve survival in LVAD recipients.
Authors: Rakesh Gopinathannair; Naga Venkata K Pothineni; Jaimin R Trivedi; Henri Roukoz; Jennifer Cowger; Mustafa M Ahmed; Adarsh Bhan; Ashwin K Ravichandran; Geetha Bhat; Amin Al Ahmad; Andrea Natale; Luigi Di Biase; Mark S Slaughter; Dhanunjaya Lakkireddy Journal: J Am Heart Assoc Date: 2022-06-03 Impact factor: 6.106
Authors: Brittney H Davis; Amelia K Boehme; Salpy V Pamboukian; Michael Allon; James F George; Chrisly Dillon; James K Kirklin; Jose Tallaj; Emily B Levitan; Russell Griffin; Gerald McGwin; T Mark Beasley; Nita A Limdi Journal: ASAIO J Date: 2020-03 Impact factor: 3.826
Authors: Finn Gustafsson; Binyamin Ben Avraham; Ovidiu Chioncel; Tal Hasin; Avishai Grupper; Aviv Shaul; Sanemn Nalbantgil; Yoav Hammer; Wilfried Mullens; Laurens F Tops; Jeremy Elliston; Steven Tsui; Davor Milicic; Johann Altenberger; Miriam Abuhazira; Stephan Winnik; Jacob Lavee; Massimo Francesco Piepoli; Lorrena Hill; Righab Hamdan; Arjang Ruhparwar; Stefan Anker; Marisa Generosa Crespo-Leiro; Andrew J S Coats; Gerasimos Filippatos; Marco Metra; Giuseppe Rosano; Petar Seferovic; Frank Ruschitzka; Stamatis Adamopoulos; Yaron Barac; Nicolaas De Jonge; Maria Frigerio; Eva Goncalvesova; Israel Gotsman; Osnat Itzhaki Ben Zadok; Piotr Ponikowski; Luciano Potena; Arsen Ristic; Tiny Jaarsma; Tuvia Ben Gal Journal: ESC Heart Fail Date: 2021-09-28